The Use of Ofatumumab in Renal Conditions

Abstract

Ofatumumab is a fully humanized monoclonal antibody against CD20. It has been initially used against hematological malignancies but now has been reported widely for autoimmune or rheumatological (e.g., rheumatoid arthritis, multiple sclerosis) and renal conditions. Over the past decade, since the first report on its use in rituximab-resistant nephrotic syndrome, there have been many more centers describing their experience with ofatumumab. Due to it being relatively new, the optimal dosing of ofatumumab for renal conditions has not been established, especially in children, and studies so far have been mainly case reports or case series. Large-scale, multi-center prospective studies are required to establish the appropriate dosing and investigate adverse reactions of ofatumumab. Reported studies on the use of ofatumumab in renal conditions and reported or potential adverse reactions are discussed in this review.